RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas

Aphrothiti J Hanrahan1, David B Solit

  • 1Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA.

Cancer Discovery
|August 14, 2012
PubMed

Insights

RAF activation can cause pancreatic tumors in mice. This suggests that combining MEK inhibitors with other treatments may help patients with pancreatic cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • RAF activation is a key event in various cancers.
  • Pancreatic intraepithelial neoplasms (PanINs) are precursors to pancreatic ductal adenocarcinomas (PDAC).
  • The role of RAF-MAPK signaling in PDAC development is under investigation.

Purpose of the Study:

  • To investigate the role of RAF activation in the development of pancreatic intraepithelial neoplasms.
  • To explore the potential of targeting the MAPK/ERK pathway in PDAC treatment.

Main Methods:

  • Utilized genetically engineered mouse models (GEMMs) to study pancreatic carcinogenesis.
  • Analyzed the induction of pancreatic intraepithelial neoplasms upon RAF activation.

Main Results:

  • RAF activation was found to be sufficient for inducing pancreatic intraepithelial neoplasms in mouse models.
  • This provides evidence for the oncogenic role of RAF signaling in pancreatic cancer initiation.

Conclusions:

  • RAF-driven signaling is a critical factor in pancreatic cancer development.
  • Combination therapies involving mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitors may offer a promising therapeutic strategy for pancreatic ductal adenocarcinomas.